Qiao J.,Peking University |
Feng H.L.,North Shore University Hospital
Human Reproduction Update | Year: 2011
Background: Polycystic ovary syndrome (PCOS) is a common metabolic dysfunction and heterogeneous endocrine disorder in women of reproductive age. Although patients with PCOS are typically characterized by increased numbers of oocytes retrieved during IVF, they are often of poor quality, leading to lower fertilization, cleavage and implantation rates, and a higher miscarriage rate. METHODS: For this review, we searched the database Medline: (1950 to January 2010) and Google for all full texts and/or abstract articles published in English with content related to oocyte maturation and embryo developmental competence. Results: The search showed that alteration of many factors may directly or indirectly impair the competence of maturating oocytes through endocrine and local paracrine/autocrine actions, resulting in a lower pregnancy rate in patients with PCOS. The extra-ovarian factors identified included gonadotrophins, hyperandrogenemia and hyperinsulinemia, although intra-ovarian factors included members of the epidermal, fibroblast, insulin-like and neurotrophin families of growth factors, as well as the cytokines. Conclusions: Any abnormality in the extra- and/or intra-ovarian factors may negatively affect the granulosa cell-oocyte interaction, oocyte maturation and potential embryonic developmental competence, contributing to unsuccessful outcomes for patients with PCOS who are undergoing assisted reproduction. © The Author 2010. Published by Oxford University Press on behalf of the European Society of Human Reproduction and Embryology.
News Article | December 12, 2016
MELVILLE, NY--(Marketwired - December 12, 2016) - North American Partners in Anesthesia (NAPA) is proud to announce Regional Director, Christopher Campese, MD, MA, MS, CHCQM will be serving as Secretary of the New York State Society of Anesthesiologists (NYSSA) for 2017. Dr. Campese was elected to a one-year term by the NYSSA's House of Delegates at their 2016 Annual Meeting in New York. In his new role, Dr. Campese, a NYSSA member since 1991, will work as part of the Executive Committee on membership issues and other matters affecting the Society. In addition, Dr. Campese further represents the organization as a member of the Governmental Affairs and Communications Committees as well as Chairman of the Bylaws and Rules Committee. Previously, Dr. Campese had served as First Assistant Secretary for NYSSA. Upon his election, Dr. Campese stated "I am extremely humbled and honored to have been elected to this position in the New York State Society of Anesthesiologists, and I look forward to continuing to serve its membership in this important role as we all work to ensure excellence in the anesthesia care delivered throughout our State." Dr. Campese is a Diplomate of the American Board of Anesthesiology and the American Board of Quality Assurance and Utilization Review Physicians. He received his medical degree from Albany Medical College in Albany, NY in 1990 and completed his postgraduate training at the Albany Medical Center. He went on to receive his Master of Arts in Theology from the Seminary of the Immaculate Conception in Huntington, NY in 2006 and a Master of Science degree in Bioethics from the Alden March Bioethics Institute of Albany Medical College in 2015. Dr. Campese has held several academic appointments during his career, including Assistant Professor of Anesthesiology at Albany Medical Center in Albany, NY and Instructor for Resident Education at North Shore University Hospital in Manhasset, NY. He is presently an Assistant Professor of Anesthesiology at the Hofstra-Northwell School of Medicine in Hempstead, NY. Encompassing a membership of approximately 3,500 anesthesiologists, the NYSSA is comprised of physicians and scientists dedicated to advancing the specialty of anesthesiology and providing the safest and highest quality patient care to the citizens of New York State. In addition, the Society is responsible for hosting the second largest Anesthesia education meeting in the world, the PostGraduate Assembly (PGA), which is being held on December 9-13, 2016 in New York, NY. About North American Partners in Anesthesia As a clinician-led organization, North American Partners in Anesthesia (NAPA) is redefining healthcare, delivering unsurpassed excellence to its partners and patients every day. In three decades, NAPA has grown to become one of the nation's leading single-specialty anesthesia and perioperative management companies, serving more than one million patients annually in more than 200 healthcare facilities throughout the Northeast, Mid-Atlantic, Midwest and Southeast. Our highly skilled teams of clinicians participate in groundbreaking leadership development and customer service training programs to deliver optimal results to patients, surgeons, healthcare administrators and staff. Through our exceptional perioperative leadership, research, innovations and state-of-the-art technologies, NAPA offers real solutions driven by evidence-based outcomes to dramatically accelerate operational efficiencies, increase satisfaction ratings and enhance safety and profitability. For more information, please visit NAPAanesthesia.com. The following files are available for download:
News Article | December 9, 2016
The International Association of HealthCare Professionals is pleased to welcome Philippe Chu, MD, Radiologist, to their prestigious organization with his upcoming publication in The Leading Physicians of the World. Dr. Chu is a highly trained and qualified radiologist with a vast expertise in all facets of his work, especially radiology and body imaging. Dr. Chu has been in practice for more than 10 years and is currently serving patients at Franklin Hospital, Department of Radiology in Manhasset, New York and is also affiliated with North Shore LIJ. Dr. Chu graduated with his Medical Degree in 2004 from SUNY Downstate Medical Center. Following his graduation, he then interned at Staten Island University Hospital, served his residency at Nassau University Medical Center, and underwent fellowship training in Body Imaging at North Shore University Hospital. Dr. Chu maintains professional memberships with the American Roentgen Ray Society, the Radiological Society of North America, the American College of Radiology, and the American Institute of Ultrasound in Medicine. Dr. Chu is certified by the American Board of Radiology, and stays up to date with the latest advances and developments in his field by attending 2-3 conferences per year. He attributes his success to his good experience in residency training, and his great mentors along the way. Learn more about Dr. Chu here: https://www.northwell.edu/find-care/find-a-doctor/diagnostic-radiology/dr-philippe-chu-md-11352653 and be sure to read his upcoming publication in The Leading Physicians of the World. FindaTopDoc.com is a hub for all things medicine, featuring detailed descriptions of medical professionals across all areas of expertise, and information on thousands of healthcare topics. Each month, millions of patients use FindaTopDoc to find a doctor nearby and instantly book an appointment online or create a review. FindaTopDoc.com features each doctor’s full professional biography highlighting their achievements, experience, patient reviews and areas of expertise. A leading provider of valuable health information that helps empower patient and doctor alike, FindaTopDoc enables readers to live a happier and healthier life. For more information about FindaTopDoc, visit:http://www.findatopdoc.com
News Article | December 5, 2016
Sabah Shah MD, MBA has joined the Retina Group of New York (RGONY) specializing in uveitis and vitreoretinal surgery. The Retina Group of New York was founded by James M. Maisel, MD and has been providing tertiary medical and surgical retinal care on Long Island for over 30 years. Dr. Shah has always followed a legacy of surpassing expectations amongst her peers. Growing up in a family of doctors, Dr. Shah emulated the role of a physician as a medical healer. At the age of 17, she was only one of 18 high school students in the entire country accepted directly into medical school from high school. She was granted direct admission into the 8-year Leadership in Medicine program at Union University and Albany Medical College. She excelled academically during her studies, attaining a dual Bachelor’s degree in Biology and Spanish, an MBA in healthcare administration, and lastly her medical degree from Albany Medical College. After graduating at the top of her class from Albany Medical College, Dr. Shah completed her internship at New York Presbyterian-Queens of Weill Cornell Medical Center. She then completed a prestigious three-year ophthalmology residency at New York University and Manhattan Eye, Ear & Throat Hospital, training under world-renowned retina specialists. Upon completing her residency training, Dr. Shah returned to upstate New York to complete a two-year combined fellowship in vitreoretinal surgery and uveitis. Dr. Shah was appointed as Assistant Professor of Ophthalmology at Albany Medical College and was awarded the Resident Teaching Award for her excellence in instructing surgical and medical techniques to residents. During her training, Dr. Shah has published numerous papers on anti-VEGF medications including Avastin, Lucentis and Eylea, and procedures that are currently used by retina specialists such as retinal detachment repair and macular pucker surgery. She has participated in ongoing clinical trials involving pathology for macular degeneration and uveitis. Furthermore, Dr. Shah has presented her research, received research scholarships and awards, and has given lectures at the national level to hundreds of physicians across the country. Dr. Maisel states, “It is a privilege to have Dr. Shah join RGONY as the only ophthalmologist on Long Island to be fellowship trained in both retina and uveitis. Dr. Shah has extensive experience in some of the most sophisticated and groundbreaking medical and surgical techniques and we look forward to having her bring that expertise to RGONY and our patients. She has performed thousands of eye injections, retina lasers, and surgery for retinal detachment, macular puckers, and vitrectomies. Her comprehensive training, coupled with her amiable personality makes her a valuable addition to our specialized tertiary retina and uveitis practice.” Dr. Shah adds, “It is an honor to be a part of the medical and surgical community specializing in the management of retina and uveitis patients in Long Island. Having grown up in Long Island, I am excited to come back to serve my community. I enjoy meeting new patients and my passion in life is my career which enables me to restore vision and independence.” About the Retina Group of New York The Retina Group of New York has provided tertiary retinal and uveitis care to patients in Nassau and Suffolk Counties since 1986 at its offices in Hicksville and Hauppauge. Both locations are fully equipped with in-office laser capabilities, cutting edge diagnostic imaging, and integrated electronic records. The group holds staff privileges at seven area hospitals and teaching appointments at the Hofstra North Shore-LIJ School of Medicine, North Shore University Hospital, and Nassau University Medical Center. The practice is limited to medical and surgical retinal and uveitis problems. These commonly include diabetic retinopathy, macular degeneration, retinal vein occlusion, retinal detachment, macula pucker, macula hole, cataract surgery complications, uveitis, retinal degenerations, Plaquenil toxicity and second opinions. The group, led by CEO and founder James M. Maisel, MD, consists of Board Certified Ophthalmologists who have additional Fellowship Training from top institutions including New York Presbyterian-Cornell Medical Center, University of Pittsburgh and Albany Medical Center. They are complemented by specialized ophthalmic certified RNs, Health Information Management Specialists and Ophthalmic Technicians.The Retina Group of New York utilizes state-of-the-art diagnostic equipment and offers in-office laser treatment for diabetic retinopathy and treatment for macular degeneration and diabetic macular edema with intravitreal medications including Eylea®, Lucentis®, Ozurdex® and Iluvien®. Keeping abreast of the latest treatments, members of the group serve on the medical advisory boards of Regeneron, Allergan, Genetech and Alimera, and lecture across the U.S. to other retina specialists about macular degeneration and diabetic retinopathy. More information is available online at http://www.rgony.com.
News Article | November 17, 2016
CHICAGO, Nov. 17, 2016 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX), a biopharmaceutical company focused on bringing innovative medicines to people with renal disease, announced presentation of additional data from its pivotal Phase 3 study for iron deficiency anemia (IDA) and non-dialysis dependent chronic kidney disease (NDD-CKD) in four posters at the American Society of Nephrology’s 2016 Kidney Week taking place November 15-20 in Chicago. Data in the posters highlight an investigational use of ferric citrate as a potential oral treatment for adults with IDA and NDD-CKD. These results are a more detailed presentation of top line results announced in March 2016. Ferric citrate (Auryxia®) is currently indicated in the U.S. as a phosphate binder for the control of serum phosphorus levels in patients with CKD on dialysis. Taken together, data in the posters demonstrate that in the Phase 3 trial, the majority of patients treated with ferric citrate, 52.1 percent (61/117), achieved the primary endpoint of ≥1 g/dL increase in hemoglobin at any point during the 16-week efficacy period, 93.4 percent (57/61) of whom had a sustained treatment effect. Increases in hemoglobin in ferric-citrate treated patients were observed as early as one to two weeks after the start of treatment. Efficacy results were consistent across groups with different baseline characteristics. These results were achieved without the concomitant use of erythropoietin-stimulating agents (ESAs) or intravenous (IV) iron. Adverse events were generally similar between treatment arms and consistent with the safety profile described in the U.S. prescribing information for Auryxia, with gastrointestinal (GI) disorders as the most common adverse event. Serum phosphorus levels stayed within target ranges for CKD. “I’m pleased to have been involved in this pivotal Phase 3 study of ferric citrate,” said Steven Fishbane, M.D., chief of nephrology for North Shore University Hospital and Long Island Jewish Medical Center. “The data presented today at Kidney Week continue to underscore ferric citrate’s ability to increase iron stores and hemoglobin in patients with CKD and IDA, and support its potential utilization in non-dialysis dependent chronic kidney disease, if approved by the FDA for this indication.” “People with chronic kidney disease suffer from a range of complications, including two that are very common, hyperphosphatemia and iron deficiency anemia,” said John Neylan, M.D., chief medical officer of Keryx Biopharmaceuticals. “We are pleased to have the opportunity to further characterize the pivotal phase 3 trial results of ferric citrate’s investigational use in a scientific forum. These data support our goal to expand ferric citrate’s label and we look forward to submitting the sNDA for IDA in NDD-CKD patients to the FDA.” About NDD-CKD, Iron Deficiency Anemia Iron deficiency anemia is a common complication in patients with non-dialysis dependent chronic kidney disease (NDD-CKD), and the prevalence and severity of IDA increases as kidney disease progresses. It is estimated that there are approximately 1.6 million people living in the U.S. with stage 3-5 non-dialysis dependent chronic kidney disease and iron deficiency anemia(1) Efficacy and tolerability of current oral iron supplements are mixed. Intravenous (IV) iron administration is associated with important risks and burdens. About the Pivotal Phase 3 Clinical Study The pivotal Phase 3 study randomized 234 patients (233 patients received at least one starting dose of ferric citrate) at 32 clinical sites in the United States. NDD-CKD patients with hemoglobin levels between 9.0 mg/dL and 11.5 mg/dL and who were intolerant to or had inadequate response to oral iron supplements were randomized 1:1 (ferric citrate versus placebo), n=117 and n=116, respectively. Patients enrolled in the study were not allowed to receive any IV or oral iron, or ESAs during this study. The study had a 16-week, randomized, double-blind, placebo-controlled, efficacy period followed by an 8-week open-label safety extension period in which all patients remaining in the study, including the placebo group, received ferric citrate. During the 16-week efficacy period, ferric citrate was administered at a starting dose of three tablets per day with food and could be titrated every four weeks by an additional three tablets for up to a maximum of 12 tablets per day; the mean dose received in ferric citrate treated patients was 5 tablets per day. The primary endpoint was the proportion of patients achieving a ≥1 g/dL increase in hemoglobin at any point during the 16-week efficacy period. Poster Presentations Four posters presented during Kidney Week are related to the Phase 3 clinical trial. Summary of Phase 3 trial data presented in four poster presentations An analysis of the 16-week randomized efficacy period of the Phase 3 data study of ferric citrate (FC) dosed to improve hemoglobin levels showed that ferric citrate was well tolerated. 52.1 percent (61/117) of ferric citrate treated patients achieved the primary endpoint without the use of IV iron or ESA compared to 19.1 percent in the placebo group. Of the patients in the ferric citrate treatment group who achieved the primary endpoint, 93 percent (57/61) had a sustained treatment effect as defined by a mean change from baseline of ≥0.75 mg/dL over any 4-week time period provided that an increase of >1.0 g/dL had occurred during that 4-week period. Increases in hemoglobin were observed as early as one to two weeks after the start of treatment with ferric citrate. Additional analyses of patients at the end of the 16-week efficacy period were conducted and reported in the posters that showed: Use of ferric citrate in patients with NDD-CKD and IDA, as highlighted above, is investigational and has not been determined to be safe or efficacious. About Auryxia Auryxia (ferric citrate) was approved by the U.S. Food and Drug Administration on September 5, 2014 and is indicated in the U.S. for the control of serum phosphorus levels in patients with CKD on dialysis. The U.S. approval of Auryxia was based on data from the company's Phase 3 registration program in dialysis patients. In the Phase 3 clinical trials, Auryxia effectively reduced serum phosphorus levels to within the KDOQI guidelines range of 3.5 to 5.5 mg/dL. Auryxia binds with dietary phosphate in the GI tract and precipitates as ferric phosphate. The unbound portion of Auryxia has been shown to increase serum iron parameters including ferritin and transferrin saturation (TSAT). Iron absorption from Auryxia may lead to excessive elevations in iron stores. Accordingly, physicians should assess and monitor iron parameters before starting and while on Auryxia, and may need to decrease or discontinue IV iron for these patients. The most common adverse events for Auryxia treated patients were gastrointestinal related, including diarrhea, nausea, vomiting and constipation. For more information about Auryxia and the U.S. full prescribing information, visit www.Auryxia.com. IMPORTANT U.S. SAFETY INFORMATION FOR AURYXIA® (ferric citrate) Contraindication: Patients with iron overload syndrome, e.g. hemochromatosis, should not take Auryxia®. Iron Overload: Iron absorption from Auryxia may lead to increased iron in storage sites. Iron parameters should be monitored prior to and while on Auryxia. Patients receiving IV iron may require a reduction in dose or discontinuation of IV iron therapy. Accidental Overdose of Iron: Accidental overdose of iron containing products is a leading cause of fatal poisoning in children under 6 years of age. Keep Auryxia away from children as it contains iron. Call a poison control center or your physician in case of an accidental overdose in a child. Patients with Gastrointestinal Bleeding or Inflammation: Safety has not been established for these patients. Adverse Events: The most common adverse events with Auryxia were diarrhea (21%), nausea (11%), constipation (8%), vomiting (7%) and cough (6%). Gastrointestinal adverse reactions were the most common reason for discontinuing Auryxia (14%). Auryxia contains iron and may cause dark stools, which is considered normal with oral medications containing iron. Drug Interactions: Doxycycline should be taken at least 1 hour before Auryxia. Ciprofloxacin should be taken at least 2 hours before or after Auryxia. For Full Prescribing Information for Auryxia, please visit http://auryxia.com/important-safety-information/ Forward Looking Statements Some of the statements included in this press release, particularly those regarding the commercialization and ongoing clinical development of Auryxia, may be forward-looking statements that involve a number of risks and uncertainties. For those statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995. Among the factors that could cause our actual results to differ materially are the following: whether we can increase adoption of Auryxia in patients with CKD on dialysis; the risk that the FDA may not concur with our interpretation of our Phase 3 study results in non-dialysis dependent (NDD) CKD, supportive data, conduct of the studies, or any other part of our regulatory submission and could ultimately deny approval of ferric citrate for the treatment of IDA in adults with stage 3-5 NDD-CKD; the risk that if approved for use in NDD-CKD that we may not be able to successfully market Auryxia for use in this indication; and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. Any forward-looking statements set forth in this press release speak only as of the date of this press release. We do not undertake to update any of these forward-looking statements to reflect events or circumstances that occur after the date hereof. This press release and prior releases are available at http://www.keryx.com. The information found on our website is not incorporated by reference into this press release and is included for reference purposes only. About Keryx Biopharmaceuticals, Inc. Keryx Biopharmaceuticals, with headquarters in Boston, is focused on bringing innovative medicines to market for people with renal disease. In December 2014, the company launched its first FDA-approved medicine, Auryxia® (ferric citrate) in the United States. In January 2014, ferric citrate was approved for use in Japan, where it is being marketed as Riona® by Keryx's Japanese partner, Japan Tobacco Inc. and Torii Pharmaceutical Co. Ltd. In September 2015, the European Commission granted European market authorization for Fexeric® (ferric citrate coordination complex). For more information about Keryx, please visit www.keryx.com.
Schulder M.,North Shore University Hospital
Acta neurochirurgica. Supplement | Year: 2011
This work aims at demonstrating the value of intraoperative magnetic resonance imaging (ioMRI) as a routine tool for stereotactic brain biopsy. Biopsies were done using the PoleStar N-20 ioMRI (Medtronic Navigation, Louisville, Colorado, USA) under general anesthesia. Images were acquired after patient positioning and after insertion of an MRI-compatible biopsy cannula. A Navigus guide (Medtronic Navigation) was used to align and direct the cannula. Retargeting was done as necessary, to improve placement within the target and to avoid critical structures, using the system's integrated infrared navigation tool. Cannula placement was tracked using serial images. ioMRI-guided biopsy was done in 39 patients, of whom 28 had neoplasms and 11 had non-neoplastic conditions. Additional OR time related to the use of ioMRI (including positioning of the patient and magnet, and imaging acquisition) averaged 1.1h. In 53% of the surgeries the biopsy cannula was repositioned based on intraoperative imaging. A histologic diagnosis was obtained in all but one patient, with ioMRI confirming proper cannula placement in all cases. There were no significant hemorrhages on clinical or imaging grounds nor any other complications. IoMRI can be routinely used for stereotactic biopsy in a regular neurosurgical operating environment. While general anesthesia is used and there is some additional time incurred from this technology the improved diagnostic yield and ability to avoid complications make ioMRI an ideal technical adjunct for brain biopsy.
Jacono A.A.,North Shore University Hospital
Aesthetic Surgery Journal | Year: 2011
Background: Modern facelift techniques have benefited from a "repopularization" of shorter incisions, limited skin elevation, and more limited dissection of the superficial musculoaponeurotic system (SMAS) and platysma in order to shorten postoperative recovery times and reduce surgical risks for patients.Objectives: The authors describe their minimal access deep plane extended (MADE) vertical vector facelift, which is a hybrid technique combining the optimal features of the deep plane facelift and the short scar, minimal access cranial suspension (MACS) lift.Methods: The authors retrospectively reviewed the case records of 181 patients who underwent facelift procedures performed by the senior author (AAJ) during a two year period between March 2008 and March 2010. Of those patients, 153 underwent facelifting with the MADE vertical technique. With this technique, deep plane dissection releases the zygomatico-cutaneous ligaments, allowing for more significant vertical motion of the midface and jawline during suspension. Extended platysmal dissection was utilized with a lateral platysmal myotomy, which is not traditionally included in a deep plane facelift. The lateral platysmal myotomy allowed for separation of the vertical vector of suspension in the midface and jawline from the superolateral vector of suspension that is required for neck rejuvenation, obviating the need for additional anterior platysmal surgery.Results: The average age of the patients was 57.8 years. The average length of follow-up was 12.7 months. In 69 consecutive patients from this series, average vertical skin excision measured 3.02 cm on each side of the face at the junction of the pre auricular and temporal hair tuft incision (resulting in a total excision of 6.04 cm of skin). Data from the entire series revealed a revision rate of 3.9%, a hematoma rate of 1.9%, and a temporary facial nerve injury rate of 1.3%.Conclusions: The common goal of all facelifting procedures is to provide a long-lasting, natural, balanced, rejuvenated aesthetic result with few complications and minimal downtime. The MADE vertical facelift fulfills these criteria and often yields superior results in the midface and neck areas, where many short scar techniques fail. Furthermore, this procedure can be performed under local anesthesia, which is a benefit to both patients and surgeons. © 2011 American Society for Aesthetic Plastic Surgery, Inc.
News Article | February 15, 2017
The American Diabetes Association of Greater New York and the Retina Group of New York proudly announce the 2017 EXPO being held on March 11, 2017, in the North Wing of the Jacob Javits Convention Center from 10am to 4pm. The Retina Group of New York, a leading Long Island group of vitreoretinal physicians, will be a presenting sponsor. James M. Maisel, MD, Founder and CEO of the Retina Group of New York will be speaking on “Advances in Diabetic Retinopathy Prevention, Diagnosis and Treatment.” This free community event will feature complimentary health screenings, healthy cooking demonstrations from celebrity chefs, exercise tips from nutrition and fitness experts, access to healthcare providers, multilingual presentations regarding diabetes prevention, multicultural community areas, a living-with-type 1 diabetes area, and a diabetes-goes-digital area. “The Retina Group of New York is committed to raising awareness about the need for regular screening for all diabetic patients for diabetic retinopathy, and in the prevention, diagnosis and treatment of diabetic retinopathy. In addition to faster and more accurate diagnosis of diabetic retinopathy, we are not only able to prevent blindness in almost all patients with laser and vitreous microsurgery, we can often improve vision with newer FDA approved medications,” said Dr. Maisel. “We are proud to serve as a presenting sponsor of the American Diabetes Association EXPO and to help reduce the prevalence of this preventable disease.” More than 10,000 attendees are expected from the Greater New York region. The EXPO aims to attract families affected by diabetes as well as those interested in learning how to live healthier, active lifestyles and changing the future of diabetes. “Every 11 seconds someone is diagnosed with diabetes,” said James Sheridan, Regional Vice President at the American Diabetes Association. “The fact is, nearly 30 million adults and children in the United States have diabetes—nearly 10 percent of the population. That percentage is even higher in New York City, reaching 14% in the African American and Latino population. And shockingly, many do not even know that they have the disease. That is why screening is so important.” Free, early registration is available at http://www.diabetes.org/exponyc About the American Diabetes Association The American Diabetes Association is leading the fight to Stop Diabetes® and its deadly consequences and fighting for those affected by diabetes. The Association funds research to prevent, cure and manage diabetes; delivers services to hundreds of communities; provides objective and credible information; and gives voice to those denied their rights because of diabetes. Founded in 1940, the Association’s mission is to prevent and cure diabetes, and to improve the lives of all people affected by diabetes. For more information, please call the American Diabetes Association at 1-800-DIABETES (1-800-342-2383) or visit diabetes.org. Information from both of these sources is available in English and Spanish. About The Retina Group of New York The Retina Group of New York has provided tertiary vitreoretinal care to patients in Nassau and Suffolk Counties since 1986 at its offices in Hicksville and Hauppauge. Both locations are fully equipped with in-office laser capabilities, cutting-edge diagnostic equipment, and integrated electronic records. The group holds staff privileges at eight area hospitals and teaching appointments at the Hofstra Northwell School of Medicine, North Shore University Hospital, and NuHealth Nassau University Medical Center. The practice is limited to medical and surgical retinal problems. These commonly include diabetic retinopathy, macular degeneration, retinal vein occlusion, retinal detachment, macular pucker, macula hole, surgery complications, uveitis, Plaquenil toxicity and second opinions. For more information on The Retina Group of New York, visit http://www.rgony.com, or call 516-939-6100 or 631-273-1818 for appointments.
News Article | October 27, 2016
A man who was believed to have introduced HIV to North America — the man sometimes referred to as "Patient Zero" — was actually not the initial source of the virus on this continent, new research shows. Rather, this man was one of the thousands of people in North America who were infected with HIV in the years before the virus was officially recognized, according to the new findings published today (Oct. 26) in the journal Nature. The man, Gaétan Dugas, was a Canadian flight attendant, and was thought to have introduced HIV into one or more major U.S. cities by infecting his sexual partners, setting off the AIDS crisis that struck the U.S. in the 1980s, the researchers said. Dugas died from AIDS in 1984. "Gaétan Dugas is one of the most demonized patients in history, and one of a long line of individuals and groups vilified in the belief that they somehow fuelled epidemics with malicious intent," study co-author Richard McKay, a historian at the University of Cambridge in England, said in a statement. [Top 10 Stigmatized Health Disorders] The first AIDS patients were recognized in San Francisco and other places in California, in 1981. But the new results show that the human immunodeficiency virus (HIV), which causes AIDS, likely first arrived in the U.S. in New York City in 1970, the researchers said. In the study, the researchers looked at historical and genetic evidence to figure out exactly how and when the HIV virus emerged in North America. They conducted genetic testing of blood samples collected during 1978 and 1979 from men living in New York and San Francisco who were later found to be infected with HIV. The researchers used a new technique, called "RNA jackhammering," which allowed them to break down the genetic material of the virus within the blood samples into smaller chunks, and extract one of the most crucial components of the virus, called RNA. They used the information they found to construct an evolutionary "family tree" of the virus. The findings showed that the HIV circulating in the U.S. was already surprisingly genetically diverse in the late 1970s, the researchers said. The findings also showed that it was the arrival of HIV in New York that sparked the North American HIV epidemic, the researchers said. The city wasthe crucial hub from which the virus spread across the continent, including to San Francisco, they said. [The 9 Deadliest Viruses on Earth] "Our analysis shows that the outbreaks in California that first caused people to ring the alarm bells and led to the discovery of AIDS were really just offshoots of the earlier outbreak that we see in New York City," study co-author Michael Worobey, a professor of ecology and evolutionary biology at the University of Arizona, said in a statement. Moreover, the researchers looked at genetic material from Dugas and found that he was not the source of the virus's epidemic in the U.S. "This individual was simply one of thousands infected before HIV/AIDS was recognized," McKay said during a news briefing on the findings. Dugas was once designated as Patient "O" (as in the letter "O") by investigators in the 1980s who conducted an early study on AIDS cases in California. The designation was used because Dugas was from "Out(side)-of-California." However, that "O" nickname was later misinterpreted as a "0" (as in the number zero) and contributed to the labeling of the man as "Patient 0," which people thought meant that he was the first case in the outbreak, the researchers found. The new results show that, when it comes to the start of the HIV epidemic in North America, "it was not a single bad actor," said Dr. Bruce Hirsch, an attending physician of infectious diseases at North Shore University Hospital in Manhasset, New York, who was not involved in the study. Overall, the origins of epidemics can usually be traced back to communities of vulnerable individuals, but not to a single person, he told Live Science. "I think that is an important way of understanding HIV and other epidemics," he said.
News Article | April 22, 2016
In a bid to save her niece's life who was in urgent need of a kidney transplant, an aunt created a three-way kidney swap daisy chain. In this unique kidney swap daisy chain, a set of three pairs of people were involved - an aunt and her niece, a daughter-in-law and her mother-in-law, and a husband and his wife. They were not matched to be the donor for their loved ones, and hence became a part of a unique chain when the donor from one pair donated a kidney to the receptor from another pair. It all began when Dawn Bates wanted to donate her kidney to her niece, Nicole Johnson. However, the match didn't come through. Not giving up, Dawn looked up the living donor registry and it was revealed that a certain Catherine Richards, a complete stranger, was an ideal match. While Catherine agreed to donate her kidney to Nicole, it turned out her mother-in-law, Elaine Richards, who she was incompatible with, found a perfect match in another donor, Terry Fung Ching. And finally, Terry's wife Tiffany, who also needed a kidney transplant, found a matched donor in Dawn Bates completing the full cycle. The doctors said that though the daisy chain swap was complicated, the success rate is higher and the patients live longer with organs received from a living donor. And with more than 100,000 people awaiting kidney transplant, the rise in living donor volunteers throughout the country, using daisy chain, puts the odds of finding a match in a critical situation at a much better level. All six donors and recipients met up for the first time on April 21 at North Shore University Hospital, New York, for a news conference. The doctor present at the conference mentioned that the waiting time for organ transplant for some blood types can take up to 5 to 7 years or more. "I just planted the seeds and this is a beautiful garden. It is a wonderful feeling," said Bates, among hugs, smiles and tears of joy. Dr. Nicole Ali, director of the hospital's transplant center said that this unique organ swap came into being only because of the selfless nature of all three donors - Dawn Bates, Catherine Richards and Terry Fung Ching. © 2017 Tech Times, All rights reserved. Do not reproduce without permission.